Начало › Множествен миелом › Северна Каролина › Durham
Клинични проучвания за Множествен миелом в Durham, NC
37 проучвания за Множествен миелом търсят участници в обекти в и около Durham (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Набиране на участнициФаза 3
- Research Site, Chapel Hill · на 10 мили
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Набиране на участнициФаза 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · на 10 мили
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Набиране на участнициФаза 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Набиране на участнициФаза 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · на 10 мили
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Набиране на участнициФаза 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набиране на участнициФаза 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 2
- University of North Carolina Medical Center, Chapel Hill · на 10 мили
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Набиране на участнициФаза 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · на 10 мили
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Набиране на участнициФаза 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · на 13 мили
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Набиране на участнициФаза 1/2
- GSK Investigational Site, Chapel Hill · на 10 мили
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Набиране на участнициФаза 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Набиране на участнициФаза 3
- Research Site, Durham
- Research Site, Chapel Hill · на 10 мили
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Набиране на участници
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · на 10 мили
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Набиране на участнициФаза 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · на 10 мили
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Набиране на участнициФаза 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · на 10 мили
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Набиране на участнициФаза 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- University of North Carolina /ID# 251203, Chapel Hill · на 10 мили
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Набиране на участнициФаза 1
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Набиране на участнициФаза 2
- University of North Carolina (Data Collection Only), Chapel Hill · на 10 мили
Registry of Older Patients With Cancer
Набиране на участнициНаблюдателно проучване
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 мили
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Набиране на участнициФаза 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Набиране на участнициФаза 2
- University of North Carolina, Chapel Hill · на 10 мили
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Набиране на участнициФаза 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · на 10 мили
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Набиране на участнициФаза 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · на 13 мили
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Набиране на участнициФаза 1
- University of North Carolina, Chapel Hill · на 10 мили
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Набиране на участнициФаза 1
- University of North Carolina, Chapel Hill · на 10 мили
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набиране на участнициФаза 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · на 10 мили
Registry for Adults With Plasma Cell Disorders (PCD's)
Набиране на участнициНаблюдателно проучване
- North Carolina Cancer Hospital, Chapel Hill · на 10 мили
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Набиране на участнициНаблюдателно проучване
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 мили
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Duke University Health System (DUHS), Durham
Проучвания за Множествен миелом в други градове
- New York City, NY60 проучвания
- Boston, MA42 проучвания
- Atlanta, GA41 проучвания
- Houston, TX38 проучвания
- Nashville, TN32 проучвания
- Denver, CO27 проучвания
- Rochester, MN24 проучвания
- St. Louis, MO24 проучвания
- Columbus, OH24 проучвания
- Baldwin Park, CA23 проучвания
- Chicago, IL22 проучвания
- Seattle, WA22 проучвания
Други проучвания в Durham
- Рак на гърдата63 проучвания
- Рак (всички видове)58 проучвания
- Рак на белия дроб с недребноклетъчен тип39 проучвания
- Метастатичен рак33 проучвания
- Остра миелоидна левкемия33 проучвания
- Рак на белия дроб32 проучвания
- Рак на простатата32 проучвания
- Колоректален рак28 проучвания
- Хронична лимфоцитна левкемия27 проучвания
- Рак на яйчниците27 проучвания
- Сърдечна недостатъчност26 проучвания
- Рак на панкреаса24 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.